Evidence map›Paper›PMID 35073946›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation.

Zivojin Jevtic, Vittoria Matafora, Francesca Casagrande, Fabio Santoro, Saverio Minucci, Massimilliano Garre', Milad Rasouli, Olaf Heidenreich, Giovanna Musco, Jürg Schwaller and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Phase Separation in Chromatin Organization and Human Diseases.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Transcription regulation by biomolecular condensates.Nature reviews. Molecular cell biology · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Zivojin JevticFunctional Proteomics group, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy.
Vittoria MataforaFunctional Proteomics group, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy.
Francesca CasagrandeImaging Technological Development Unit, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy.
Fabio SantoroChromatin Alterations in Tumorigenesis Unit, European Institute of Oncology, Milan, Italy.
Saverio MinucciChromatin Alterations in Tumorigenesis Unit, European Institute of Oncology, Milan, Italy.
Massimilliano Garre'Imaging Technological Development Unit, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy.
Milad RasouliPrinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Olaf HeidenreichPrinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Giovanna MuscoBiomolecular NMR, IRCCS Ospedale San Raffaele, Milan, Italy.
Jürg SchwallerDepartment for Biomedicine, University Children Hospital, Basel, Switzerland. j.schwaller@unibas.ch.
Angela BachiFunctional Proteomics group, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy. angela.bachi@ifom.eu.ORCID http://orcid.org/0000-0003-4842-6556
IFOM · ITPrincess Máxima Center · NLEuropean Institute of Oncology · ITIRCCS Ospedale San Raffaele · ITUniversity Children’s Hospital Basel · CHUniversity of Milan · IT

Funding

associazione italiana per la ricerca sul cancro IG 18607ministero della salute RF-2013-02354880
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is characterized by accumulation of aberrantly differentiated hematopoietic myeloid progenitor cells. The karyotyping-silent NUP98-NSD1 fusion is a molecular hallmark of pediatric AML and is associated with the activating FLT3-ITD mutation in > 70% of the cases. NUP98-NSD1 fusion protein promotes myeloid progenitor self-renewal in mice via unknown molecular mechanism requiring both the NUP98 and the NSD1 moieties.

methodsWe used affinity purification coupled to label-free mass spectrometry (AP-MS) to examine the effect of NUP98-NSD1 structural domain deletions on nuclear interactome binding. We determined their functional relevance in NUP98-NSD1 immortalized primary murine hematopoietic stem and progenitor cells (HSPC) by inducible knockdown, pharmacological targeting, methylcellulose assay, RT-qPCR analysis and/or proximity ligation assays (PLA). Fluorescence recovery after photobleaching and b-isoxazole assay were performed to examine the phase transition capacity of NUP98-NSD1 in vitro and in vivo.

resultsWe show that NUP98-NSD1 core interactome binding is largely dependent on the NUP98 phenylalanine-glycine (FG) repeat domains which mediate formation of liquid-like phase-separated NUP98-NSD1 nuclear condensates. We identified condensate constituents including imitation switch (ISWI) family member SMARCA5 and BPTF (bromodomain PHD finger transcription factor), both members of the nucleosome remodeling factor complex (NURF). We validated the interaction with SMARCA5 in NUP98-NSD1

conclusionsNUP98-NSD1 interacts and colocalizes on the genome with SMARCA5 which is an essential mediator of the NUP98-NSD1 transformation in hematopoietic cells. Formation of NUP98-NSD1 phase-separated nuclear condensates is not sufficient for the maintenance of transformed phenotype, which suggests that selective targeting of condensate constituents might represent a new therapeutic strategy for NUP98-NSD1 driven AML.

Indexed as

Adenosine TriphosphatasesAnimalsChromosomal Proteins, Non-HistoneHematopoiesisHumansMiceNuclear Pore Complex ProteinsProteomicsAdenosine TriphosphatasesChromosomal Proteins, Non-Histonenuclear pore complex protein 98Nuclear Pore Complex ProteinsSmarca5 protein, mouseAcute myeloid leukemiaInteractomicsNUP98-NSD1Phase-separationSMARCA5

Identifiers

PMID35073946
PMCPMC8785526
OpenAlexW4206942201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.